Defactinib inhibits FAK phosphorylation and regulates psoriasis via attenuating hyperproliferation of keratinocytes
Yuyue Zuo
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hubei, China
Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan, Hubei, China
Search for more papers by this authorYueqi Zhang
Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Hubei Provincial Engineering Research Center of Vascular Interventional Therapy, Wuhan, Hubei, China
Search for more papers by this authorZilu Qu
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hubei, China
Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan, Hubei, China
Search for more papers by this authorBei Wang
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hubei, China
Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan, Hubei, China
Search for more papers by this authorYan Zhao
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hubei, China
Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan, Hubei, China
Search for more papers by this authorLei Dai
Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Hubei Provincial Engineering Research Center of Vascular Interventional Therapy, Wuhan, Hubei, China
Search for more papers by this authorCorresponding Author
Liuqing Chen
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hubei, China
Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan, Hubei, China
Correspondence
Li Xu and Liuqing Chen, Tongji Medical College, Huazhong University of Science and Technology, Wuhan No. 1 Hospital, No. 215, Zhongshan Avenue, Wuhan 430022, Hubei, China.
Email: [email protected] and [email protected]
Search for more papers by this authorCorresponding Author
Li Xu
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hubei, China
Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan, Hubei, China
Correspondence
Li Xu and Liuqing Chen, Tongji Medical College, Huazhong University of Science and Technology, Wuhan No. 1 Hospital, No. 215, Zhongshan Avenue, Wuhan 430022, Hubei, China.
Email: [email protected] and [email protected]
Search for more papers by this authorYuyue Zuo
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hubei, China
Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan, Hubei, China
Search for more papers by this authorYueqi Zhang
Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Hubei Provincial Engineering Research Center of Vascular Interventional Therapy, Wuhan, Hubei, China
Search for more papers by this authorZilu Qu
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hubei, China
Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan, Hubei, China
Search for more papers by this authorBei Wang
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hubei, China
Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan, Hubei, China
Search for more papers by this authorYan Zhao
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hubei, China
Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan, Hubei, China
Search for more papers by this authorLei Dai
Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Hubei Provincial Engineering Research Center of Vascular Interventional Therapy, Wuhan, Hubei, China
Search for more papers by this authorCorresponding Author
Liuqing Chen
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hubei, China
Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan, Hubei, China
Correspondence
Li Xu and Liuqing Chen, Tongji Medical College, Huazhong University of Science and Technology, Wuhan No. 1 Hospital, No. 215, Zhongshan Avenue, Wuhan 430022, Hubei, China.
Email: [email protected] and [email protected]
Search for more papers by this authorCorresponding Author
Li Xu
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hubei, China
Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan, Hubei, China
Correspondence
Li Xu and Liuqing Chen, Tongji Medical College, Huazhong University of Science and Technology, Wuhan No. 1 Hospital, No. 215, Zhongshan Avenue, Wuhan 430022, Hubei, China.
Email: [email protected] and [email protected]
Search for more papers by this authorYuyue Zuo and Yueqi Zhang have contributed equally to this work and shared first authorship.
Abstract
Excessive proliferation of keratinocytes is a crucial pathological risk feature of psoriasis. Focal adhesion kinase (FAK) is a non-receptor protein that primarily regulates cell proliferation and migration. However, the expression and regulatory mechanism of FAK in psoriasis remains unclear. This study aimed to investigate the regulation of FAK in psoriasis and examined the potential impact of FAK inhibitor on psoriasis. A small molecular selective FAK inhibitor, defactinib, was used to evaluate the effect of FAK on psoriasis in in vitro and in vivo functional assays. In our experiments, imiquimod (IMQ)-induced psoriasis mice and human keratinocytes cells were used to study the potential roles and mechanisms of FAK in psoriasis. FAK phosphorylation has been weakly detected in normal intact skin and is markedly elevated upon IMQ treatment. By reducing FAK phosphorylation (p-FAK), defactinib treatment could attenuate psoriasiform inflammation and epidermal hyperplasia in IMQ-treated mice compared with IMQ-induced mice treated with the vehicle. In in vitro studies, resiquimod (R848) increased (p-FAK) and promoted cell proliferation in human keratinocytes cells, while defactinib reversed this effect. Mechanistically, defactinib can alleviate the proliferation via JNK/YB1 pathway in vitro and in vivo. Defactinib significantly attenuates psoriasiform inflammation and epidermal hyperproliferation through the inhibition of the FAK-mediated axis. The downregulation of phosphorylated FAK then suppressed the activation of JNK/YB1 protein signaling pathway in psoriasis. Our work highlights targeting FAK as a potentially effective strategy for the treatment of psoriasis.
CONFLICT OF INTEREST STATEMENT
None declared.
Supporting Information
Filename | Description |
---|---|
jde17366-sup-0001-DataS1.docxWord 2007 document , 484.7 KB |
Data S1. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023; 8: 437.
- 2Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021; 397: 754–766.
- 3Szilveszter KP, Németh T, Mócsai A. Tyrosine kinases in autoimmune and inflammatory skin diseases. Front Immunol. 2019; 10: 1862.
- 4Bonelli M, Kerschbaumer A, Kastrati K, Ghoreschi K, Gadina M, Heinz LX, et al. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann Rheum Dis. 2023; 83: 139–160.
10.1136/ard-2023-223850 Google Scholar
- 5Roskoski R Jr. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis. Pharmacol Res. 2023; 189:106642.
- 6Markham A, Duggan S. Tirbanibulin: first approval. Drugs. 2021; 81: 509–513.
- 7Dawson JC, Serrels A, Stupack DG, Schlaepfer DD, Frame MC. Targeting FAK in anticancer combination therapies. Nat Rev Cancer. 2021; 21: 313–324.
- 8Chen X, Zhao Y, Wang X, Lin Y, Zhao W, Wu D, et al. FAK mediates LPS-induced inflammatory lung injury through interacting TAK1 and activating TAK1-NFκB pathway. Cell Death Dis. 2022; 13: 589.
- 9Jin B, Wang J, Chen Y, Zuo W, Hong B, Li J, et al. Focal adhesion kinase induces cardiac remodeling through NF-κB-mediated inflammatory responses in diabetic cardiomyopathy. Int Immunopharmacol. 2023; 120:110280.
- 10Wang X, Liu X, Duan X, Zhu K, Zhang S, Gan L, et al. Ten-eleven translocation-2 regulates DNA Hydroxymethylation status and Psoriasiform dermatitis progression in mice. Acta Derm Venereol. 2018; 98: 585–593.
- 11Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001; 25: 402–408.
- 12Liu X, Wang X, Duan X, Poorun D, Xu J, Zhang S, et al. Lipoxin A4 and its analog suppress inflammation by modulating HMGB1 translocation and expression in psoriasis. Sci Rep. 2017; 7: 7100.
- 13Tan X, Yan Y, Song B, Zhu S, Mei Q, Wu K. Focal adhesion kinase: from biological functions to therapeutic strategies. Exp Hematol Oncol. 2023; 12: 83.
- 14Kuenzi BM, Remsing Rix LL, Stewart PA, Fang B, Kinose F, Bryant AT, et al. Polypharmacology-based ceritinib repurposing using integrated functional proteomics. Nat Chem Biol. 2017; 13: 1222–1231.
- 15Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013; 105: 1485–1495.
- 16Zhang X, Li X, Wang Y, Chen Y, Hu Y, Guo C, et al. Abnormal lipid metabolism in epidermal Langerhans cells mediates psoriasis-like dermatitis. JCI Insight. 2022; 7:e150223.
- 17Wang Z, Sun Y, Lou F, Bai J, Zhou H, Cai X, et al. Targeting the transcription factor HES1 by L-menthol restores protein phosphatase 6 in keratinocytes in models of psoriasis. Nat Commun. 2022; 13: 7815.
- 18Long Z, Zuo Y, Li R, Le Y, Dong Y, Yan L. Design, synthesis and biological evaluation of 4-arylamino-pyrimidine derivatives as focal adhesion kinase inhibitors. Bioorg Chem. 2023; 140:106792.
- 19Peinemann F, Harari M, Peternel S, Chan T, Chan D, Labeit AM, et al. Indoor balneophototherapy for chronic plaque psoriasis: abridged Cochrane review. Dermatol Ther. 2021; 34:e14588.
- 20Wraight CJ, White PJ, McKean SC, Fogarty RD, Venables DJ, Liepe IJ, et al. Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides. Nat Biotechnol. 2000; 18: 521–526.
- 21Guan JL, Shalloway D. Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature. 1992; 358: 690–692.
- 22Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014; 14: 598–610.
- 23Wu CC, Pan MR, Shih SL, Shiau JP, Wu CC, Chang SJ, et al. Combination of FAK inhibitor and cytokine-induced killer cell therapy: An alternative therapeutic strategy for patients with triple-negative breast cancer. Biomed Pharmacother. 2023; 163:114732.
- 24Gao J, Yao Y, Liu C, Xie X, Li D, Liu P, et al. Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling. Int J Biol Sci. 2023; 19: 2711–2724.
- 25McLean GW, Komiyama NH, Serrels B, Asano H, Reynolds L, Conti F, et al. Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes Dev. 2004; 18: 2998–3003.
- 26Ma K, Kwon SH, Padmanabhan J, Duscher D, Trotsyuk AA, Dong Y, et al. Controlled delivery of a focal adhesion kinase inhibitor results in accelerated wound closure with decreased scar formation. J Invest Dermatol. 2018; 138: 2452–2460.
- 27Wong VW, Rustad KC, Akaishi S, Sorkin M, Glotzbach JP, Januszyk M, et al. Focal adhesion kinase links mechanical force to skin fibrosis via inflammatory signaling. Nat Med. 2011; 18: 148–152.
- 28Jia Y, Hu J, An K, Zhao Q, Dang Y, Liu H, et al. Hydrogel dressing integrating FAK inhibition and ROS scavenging for mechano-chemical treatment of atopic dermatitis. Nat Commun. 2023; 14: 2478.
- 29Jones SF, Siu LL, Bendell JC, Cleary JM, Razak AR, Infante JR, et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Investig New Drugs. 2015; 33: 1100–1107.
- 30Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with Merlin-stratified pleural mesothelioma: COMMAND-A double-blind, randomized, phase II study. J Clin Oncol. 2019; 37: 790–798.
- 31Wang-Gillam A, Lim KH, McWilliams R, Suresh R, Lockhart AC, Brown A, et al. Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: a phase I dose escalation and expansion study. Clin Cancer Res. 2022; 28: 5254–5262.
- 32Wang JZ, Zhu H, You P, Liu H, Wang WK, Fan X, et al. Upregulated YB-1 protein promotes glioblastoma growth through a YB-1/CCT4/mLST8/mTOR pathway. J Clin Invest. 2022; 132:e146536.
- 33Alkrekshi A, Wang W, Rana PS, Markovic V, Sossey-Alaoui K. A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistance. Cell Signal. 2021; 85:110073.
- 34Rybalkina EY, Moiseeva NI. Role of YB-1 protein in inflammation. Biochemistry Biokhimiia. 2022; 87: S94–S202.
- 35Wu W, Xu J, Gao D, Xie Z, Chen W, Li W, et al. TOPK promotes the growth of esophageal cancer in vitro and in vivo by enhancing YB1/eEF1A1 signal pathway. Cell Death Dis. 2023; 14: 364.